Analytical Data
-
基因名
SLC38A2
- Application
-
别名
ATA2; KIAA1382; SAT2; SNAT2
-
种属
Human
-
表达系统
HEK293
-
标签
His;MBP;Flag
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96QD8-1
-
表达区间
K2-H506
-
蛋白长度
Partial
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC38A2, a member of the SLC38 family of sodium-coupled amino acid transporters, plays a crucial role in the transport of neutral amino acids across cellular membranes. This transporter is highly expressed in various tissues, particularly in the brain, where it is implicated in maintaining amino acid homeostasis and neurotransmitter synthesis. Dysregulation of SLC38A2 has been associated with several neurological disorders, highlighting its importance in neurobiology. Research on the recombinant SLC38A2 protein involves the expression and characterization of this transporter to understand its functional properties, substrate specificity, and transport mechanisms. By generating a recombinant form of SLC38A2, scientists can investigate the effects of specific mutations and identify potential pharmacological targets for the treatment of diseases linked to amino acid transport deficiencies. Additionally, studying the structure-function relationships of SLC38A2 will advance our understanding of membrane transport processes and pave the way for developing novel therapeutic strategies aimed at modulating amino acid transport in various pathological conditions.
